PROK

#2866
ProKidney Corp. - Class A Ordinary Shares
1.8 2 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.81
1.83
Intervallo Annuale
1.30
2.60
Variazione giornaliera
-0.55%
Variazione Mensile
+18.18%
Variazione di 6 mesi
-15.74%
Variazione Annuale
-12.50%
Chiusura Precedente
1.8 3
Open
1.8 2
Minimo
1.8 1
Massimo
1.8 3
Volume
107
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
PROKIDNEY CORP. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PROKIDNEY CORP. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PROKIDNEY CORP. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PROKIDNEY CORP. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
PROKIDNEY CORP. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
PROKIDNEY CORP. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PROKIDNEY CORP. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
PROKIDNEY CORP. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
PROKIDNEY CORP. annual report, FY2025
10-K
Current report, Q4 FY2025
PROKIDNEY CORP. current report, Q4 FY2025
8-K

PROKIDNEY CORP. current report, Q1 FY2024

Full document

Business Context and Reporting Period

Company: ProKidney Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2024
Reporting Period: Event date January 19, 2024
Business Context: The Company, an emerging growth company incorporated in the Cayman Islands, entered into a material definitive agreement to facilitate the sale of its Class A ordinary shares.

Key Financial Metrics

This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point relates to the potential capital raise:

  • Maximum Offering Size: Up to $100,000,000 in aggregate offering price.
  • Compensation to Sales Agent: Up to 3.0% of gross offering proceeds.
  • Underlying Instrument: Class A ordinary shares, $0.0001 par value per share.

Material Changes

The material change reported is the execution of an Open Market Sale Agreement (the "Sales Agreement") with Jefferies LLC. This agreement establishes an "at-the-market" (ATM) facility allowing the Company to sell shares through the Sales Agent on The Nasdaq Capital Market or other venues. The Company retains the right to suspend the offering at any time and has no obligation to sell any shares.

Guidance, Outlook, and Risks

Management Commentary: The filing indicates the Company intends to use this facility to raise capital from time to time in the ordinary course of business. The agreement is based on a shelf registration statement (Form S-3) filed in November 2023.
Risks and Contingencies:

  • Dilution: Future sales of shares under this agreement will result in dilution to existing shareholders.
  • Market Conditions: Sales are subject to market conditions and the Company's discretion to suspend the offering.
  • Legal Obligations: The Company agreed to indemnify the Sales Agent against certain liabilities under the Securities Act and the Exchange Act.
Unusual Items: None reported in this filing.

Investor Verification Checklist

  • Verify the current share price and outstanding share count to assess potential dilution impact from a $100 million offering.
  • Review the Company's most recent 10-K or 10-Q to understand current cash runway and liquidity needs driving this ATM facility.
  • Confirm the status of the underlying Form S-3 registration statement (File No. 333-275701) and any subsequent prospectus supplements.
  • Monitor future 8-K filings for actual sales volumes and proceeds generated under this agreement.

Notizie